Company Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases.
Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer.
In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis.
Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab.
Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
| Country | United States |
| Founded | 2014 |
| IPO Date | Mar 23, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Richard Miller |
Contact Details
Address: 863 Mitten Road, Suite 102 Burlingame, California 94010 United States | |
| Phone | 650 900 4520 |
| Website | corvuspharma.com |
Stock Details
| Ticker Symbol | CRVS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001626971 |
| CUSIP Number | 221015100 |
| ISIN Number | US2210151005 |
| Employer ID | 46-4670809 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Richard A. Miller M.D. | Co-Founder, President, Chief Executive Officer and Chairman of the Board |
| Dr. Peter A. Thompson FACP, M.D. | Co-Founder and Independent Director |
| Leiv Lea | Chief Financial Officer |
| Dr. William Benton Jones Ph.D. | Senior Vice President of Pharmaceutical Development |
| Dr. James T. Rosenbaum M.D. | Senior Vice President of Research |
| Jeffrey S. Arcara | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 23, 2024 | 8-K | Current Report |
| Aug 15, 2024 | EFFECT | Notice of Effectiveness |
| Aug 13, 2024 | UPLOAD | Filing |
| Aug 6, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |
| Aug 1, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |